ALK | Allergy solutions for life
ALK

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

News

  • Post date
    08/16/2021
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    08/11/2021
    Six-month interim report (Q2) 2021
  • Post date
    08/09/2021
    ALK upgrades its full-year financial outlook
  • Post date
    08/05/2021
    Change to ALK’s Board of Directors
  • Post date
    08/05/2021
    Release date of six-month interim report (Q2) 2021 for ALK and audio cast
  • Post date
    07/30/2021
    ALK and Grandpharma team up to market the first adrenaline autoinjector in China
  • Post date
    07/10/2021
    New, large, ‘real-world evidence’ study by ALK of AIT’s long-term effects on allergy and asthma presented at EAACI Congress
  • Post date
    05/10/2021
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    05/05/2021
    Three-month interim report (Q1) 2021
Strategy update: Focus areas during 2021-23
Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.
ALK rewards excellence in allergy
The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy.

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.